阿斯利康(AZN.US)罕见病药物试验未达预期，股价小幅下跌

智通财经2025-07-16

智通财经APP获悉，阿斯利康(AZN.US)在研药物安塞拉米单抗针对AL淀粉样变性的Ⅲ期临床试验未能达到延长患者生存期或减少心脏相关住院次数的主要终点，这一结果与此前业界对重症患者可能获益的期待形成落差。根据美国国立卫生研究院(NIH)数据，AL淀粉样变性在美国的发病率约为12例/百万人年，中国肾活检资料显示其占继发性肾脏病患者的4%，患者确诊时平均年龄63岁，男性占比略高。尽管整体试验数据未达...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551235871?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-16 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551235871","market":"hk","top_or_hot":-1,"title":"阿斯利康(AZN.US)罕见病药物试验未达预期，股价小幅下跌","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，阿斯利康(AZN.US)在研药物安塞拉米单抗针对AL淀粉样变性的Ⅲ期临床试验未能达到延长患者生存期或减少心脏相关住院次数的主要终点，这一结果与此前业界对重症患者可能获益的期待形成落差。根据美国国立卫生研究院(NIH)数据，AL淀粉样变性在美国的发病率约为12例/百万人年，中国肾活检资料显示其占继发性肾脏病患者的4%，患者确诊时平均年龄63岁，男性占比略高。尽管整体试验数据未达...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318666.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康(AZN.US)罕见病药物试验未达预期，股价小幅下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康(AZN.US)罕见病药物试验未达预期，股价小幅下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-16 20:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1318666.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，阿斯利康(AZN.US)在研药物安塞拉米单抗针对AL淀粉样变性的Ⅲ期临床试验未能达到延长患者生存期或减少心脏相关住院次数的主要终点，这一结果与此前业界对重症患者可能获益的期待形成落差。根据美国国立卫生研究院(NIH)数据，AL淀粉样变性在美国的发病率约为12例/百万人年，中国肾活检资料显示其占继发性肾脏病患者的4%，患者确诊时平均年龄63岁，男性占比略高。尽管整体试验数据未达...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318666.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1318666.html","article_id":"2551235871","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551235871","pubTimestamp":1752670517,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，阿斯利康在研药物安塞拉米单抗针对AL淀粉样变性的Ⅲ期临床试验未能达到延长患者生存期或减少心脏相关住院次数的主要终点，这一结果与此前业界对重症患者可能获益的期待形成落差。受试验结果影响，阿斯利康股价在盘前交易阶段下跌0.61%，报收69.89美元，总市值2180亿美元。阿斯利康表示，将持续推进安塞拉米单抗的数据分析，并探索其在更精准患者群体中的适用性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4568":"美国抗疫概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","AZN":"阿斯利康","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药"},"translate_title":"AstraZeneca (AZN.US) stock falls slightly after rare disease drug trial misses expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"智通财经APP获悉，阿斯利康(AZN.US)在研药物安塞拉米单抗针对AL淀粉样变性的Ⅲ期临床试验未能达到延长患者生存期或减少心脏相关住院次数的主要终点，这一结果与此前业界对重症患者可能获益的期待形成落差。根据美国国立卫生研究院(NIH)数据，AL淀粉样变性在美国的发病率约为12例/百万人年，中国肾活检资料显示其占继发性肾脏病患者的4%，患者确诊时平均年龄63岁，男性占比略高。尽管整体试验数据未达预期，阿斯利康旗下罕见病部门Alexion首席执行官马克·杜诺耶(Marc Dunoyer)仍强调，部分患者群体显示出积极治疗反应。公司正深入分析试验细节，以挖掘潜在价值。作为首个在AL淀粉样变性中展现出临床获益的原纤维耗竭剂，安塞拉米单抗通过特异性结合错误折叠的轻链原纤维，消除器官沉积，其作用机制具有创新性。当前，AL淀粉样变性的治疗主要依赖达雷妥尤单抗等CD38单抗。Ⅲ期ANDROMEDA研究显示，达雷妥尤单抗联合化疗方案(D-VCd)可使患者完全缓解率(CR)提升至59.5%，心脏和肾脏缓解率分别达53%和58%，显著优于传统化疗。然而，现有疗法仍存在局限性：仅约20%患者符合自体造血干细胞移植条件，蛋白酶体抑制剂对晚期患者效果有限，烷化剂和免疫调节剂则存在安全性问题。受试验结果影响，阿斯利康股价在盘前交易阶段下跌0.61%，报收69.89美元，总市值2180亿美元。尽管主结果未达预期，但药物在部分患者中的有效性及作用机制突破性仍被视为积极信号。医学专家指出，安塞拉米单抗的局部成功为后续精准治疗提供了方向，尤其是针对现有疗法响应不佳的晚期患者群体。AL淀粉样变性领域的新药研发竞争激烈。除安塞拉米单抗外，CAEL-101(Anselamimab)在Ⅱ期试验中显示出清除器官淀粉样沉积的潜力，其联合化疗的1年总生存率达93%，但心脏缓解率仅27%(6/22例)，需Ⅲ期试验进一步验证。抗体偶联药物Belantamab mafodotin在早期AL淀粉样变性试验中使70%患者达到≥PR，但适应症拓展仍需大样本数据支持。此外，NEOD001等原纤维靶向药物因疗效未达预期而终止开发，凸显该领域'高风险、高回报'的研发特征。阿斯利康表示，将持续推进安塞拉米单抗的数据分析，并探索其在更精准患者群体中的适用性。随着对疾病机制的深入理解，原纤维耗竭剂有望与现有疗法形成协同效应，进一步改善患者预后。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551235871","isCrawlerRequest":true}